Meier JJ, Gethmann A, Nauck MA et al (2006) The glucagon-like peptide-1 metabolite GLP-1-(936) amide reduces postprandial glycemia independently of gastric emptying and insulin secretion in humans
Clinical trials GLP-1 RAs are an antidiabetic class of drugs, but their effect on the relative reduction in HbA1c compared to placebo was moderate (0.41.2%) in the outcome trials
GLP-1s, which have been used for years to treat type 2 diabetes, have gained widespread attention as a way to lose weight and reduce obesity-related conditions and their long-term costs
News-Medical+3EurekAlert!+3ASMBS+3 To put numbers on it: Surgical patients lost ~58 lbs in two years ( 24% of total body weight, or TBW) GLP-1 patients lost only ~12 lbs ( 4.7% TBW) over the same period EurekAlert!+2News-Medical+2 Even among GLP-1 users who continued therapy for a full year, weight loss averaged only ~7% TBWstill far less than surgical outcomes EurekAlert!+2ASMBS+2 Another rigorous analysis published in JAMA Surgery compared weight loss surgery and GLP-1 receptor agonists over two years
Katout M, Zhu H, Rutsky J, Shah P, Brook RD, Zhong J, et al
Preferred injection sites include the abdomen (at least two inches from the navel), the front of the thigh, and the back of the upper arm
)
